These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38159023)

  • 21. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
    Firneisz G
    World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
    Assarrar I; Messaoudi N; Ongoth FEM; Abdellaoui W; Malki A; Rouf S; Abda N; Ismaili Z; Latrech H
    Rev Diabet Stud; 2022 Sep; 18(3):140-145. PubMed ID: 36309775
    [No Abstract]   [Full Text] [Related]  

  • 23. Non-alcoholic fatty liver disease: a diabetologist's perspective.
    Pappachan JM; Antonio FA; Edavalath M; Mukherjee A
    Endocrine; 2014 Apr; 45(3):344-53. PubMed ID: 24287794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.
    Scapaticci S; D'Adamo E; Mohn A; Chiarelli F; Giannini C
    Front Endocrinol (Lausanne); 2021; 12():639548. PubMed ID: 33889132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.
    Pouwels S; Sakran N; Graham Y; Leal A; Pintar T; Yang W; Kassir R; Singhal R; Mahawar K; Ramnarain D
    BMC Endocr Disord; 2022 Mar; 22(1):63. PubMed ID: 35287643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
    Stefan N; Häring HU; Cusi K
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.
    Perdomo C; D'Ingianna P; Escalada J; Petta S; Romero Gómez M; Ampuero J
    Pol Arch Intern Med; 2020 Nov; 130(11):975-985. PubMed ID: 32666779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment.
    Kim KS; Lee BW; Kim YJ; Lee DH; Cha BS; Park CY
    Diabetes Metab J; 2019 Apr; 43(2):127-143. PubMed ID: 30993937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach.
    Perez-Carreras M; Casis-Herce B; Rivera R; Fernandez I; Martinez-Montiel P; Villena V
    World J Gastroenterol; 2021 Nov; 27(41):7113-7124. PubMed ID: 34887631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).
    Tanase DM; Gosav EM; Costea CF; Ciocoiu M; Lacatusu CM; Maranduca MA; Ouatu A; Floria M
    J Diabetes Res; 2020; 2020():3920196. PubMed ID: 32832560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric non-alcoholic fatty liver disease: an increasing public health issue.
    Berardis S; Sokal E
    Eur J Pediatr; 2014 Feb; 173(2):131-9. PubMed ID: 24068459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnosis and treatment of non-alcoholic fatty liver disease.
    Altinbas A; Sowa JP; Hasenberg T; Canbay A
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
    Alswat KA; Fallatah HI; Al-Judaibi B; Elsiesy HA; Al-Hamoudi WK; Qutub AN; Alturaify N; Al-Osaimi A
    Saudi Med J; 2019 Jun; 40(6):531-540. PubMed ID: 31219486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study.
    Kempiński R; Łukawska A; Krzyżanowski F; Ślósarz D; Poniewierka E
    Adv Clin Exp Med; 2019 Dec; 28(12):1615-1620. PubMed ID: 31025557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.